Navigation Links
Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
Date:6/27/2012

ncluding a SELENA/SLEDAI** improvement of 5 points or greater, no increase in a physician's global assessment of more than 0.3 points, with no new BILAG A or two or more new BILAG B organ domain scores.

About Blisibimod and PEARL-SCBAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy, immune thrombocytopenic purpura and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF's potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications.  The PEARL-SC Phase 2 study was designed as a randomized, double-blind, placebo-controlled, dose-ranging superiority trial to evaluate the safety, tolerability and efficacy of blisibimod plus standard of care, versus placebo plus standard of care.  A total of 547 patients with active SLE were randomized to receive one of three different doses of blisibimod or placebo (100 mg weekly, 200 mg weekly or 200 mg monthly) administered subcutaneously over a minimum 24-week treatment period, in addition to standard-of-care therapy. The study was conducted at multiple centers worldwide.About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan,
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Neuralstem Updates ALS Stem Cell Trial Progress
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
7. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
8. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
9. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
10. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014" ... conventional methods developed to prevent and eradicate the prevalence ... These methods are confined to low specificity, safety and ... to look for a better solution. It has been ...
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- ChemImage will present a workshop focused ... Zealand Forensic Science Society,s 22 nd International ... Adelaide, Australia .  Forensic Scientists will be ... hyperspectral imaging can bring to examination procedures. ... of Product Development at ChemImage, will host a ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
(Date:8/30/2014)... Tenn. (PRWEB) August 30, 2014 ... around the country for the past several years, ... Tennessee Hyperbaric Center have announced a scholarship program ... This announcement follows a meeting held this summer ... In recent years, reporters have shed light on ...
(Date:8/30/2014)... VA (PRWEB) August 30, 2014 Seniors Guide, ... articles recently that focus on Alzheimer’s Disease, Dementia, and ... revealed to the public of being diagnosed with the Alzheimer’s, ... latest movie, “I’ll Be Me”. The movie, out on ... while focusing on his diagnosis of the disease – which ...
(Date:8/30/2014)... 2014 Continuing to meet the skin ... with the addition of a new doctor and office ... provided leading-edge skin care in Grand Rapids since 1980 ... “As a doctor, my passion is making sure my ... Forefront Dermatology, I’m better able to focus on my ...
(Date:8/30/2014)... Hastings and Hastings, a qualified team ... Arizona is pleased to report having saved a client ... among many cases where Hastings and Hastings has tailored ... a greater portion of their settlement or recovery. The ... positive solution for Arizona car accident victims is achievable ...
(Date:8/30/2014)... 30, 2014 Market Research Report ... is a professional and in-depth market survey on ... firstly reviews the basic information of Lab Oven ... report then explores global and China’s top manufacturers ... production value, and market share etc. , The ...
Breaking Medicine News(10 mins):Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Expanding Care at the Forefront of Dermatology 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4
... , CINCINNATI, July 21 ... provider of physician office-based patient-education programs, announces the launch ... delivers real-time health content to physicians all day, every ... back office, medical news and information is sourced from ...
... the mechanics of how two types of white blood cells ... models that are used to predict how immune system cells ... Professor Phil Hodgkin, head of the institute,s Immunology Division, is ... white blood cells that are crucial to the body,s ...
... , , , OKLAHOMA ... a "D" to a "B" grade in the 2009 National Alliance on Mental ... of the nation,s public mental health care system.(1) Oklahoma showed the greatest improvement ... , , Oklahoma,s report card ...
... , BEAVERTON, Ore., July 21 ... today announced Breach Prevent for Healthcare, a customizable set of ... comply with the new HITECH Act privacy regulations. ... expands HIPAA,s privacy rules with specific data breach notification requirements ...
... , , , ... INIS) is pleased to announce the results of its annual shareholder meeting ... advancing its plans for the construction of a depleted uranium de-conversion ... , , The Company,s annual meeting was ...
... , DOYLESTOWN, Pa., July 21 ... have entered into an agreement for LaRon to co-promote Avidas, ... DK defence kit. Under the terms of the agreement, LaRon ... medicine physicians in the United States, while Avidas will continue ...
Cached Medicine News:Health News:Healthy Advice Networks Announces the Launch of PracticeWire; Technology to Deliver Real-time Healthcare Content to Physicians 2Health News:Cell division find prompts overhaul of immune response modeling 2Health News:National Report Ranks Oklahoma as a Top State for Mental Health Services 2Health News:National Report Ranks Oklahoma as a Top State for Mental Health Services 3Health News:National Report Ranks Oklahoma as a Top State for Mental Health Services 4Health News:National Report Ranks Oklahoma as a Top State for Mental Health Services 5Health News:National Report Ranks Oklahoma as a Top State for Mental Health Services 6Health News:ID Experts Offers Breach Prevent for Healthcare: A High-Touch, Affordable Solution for HITECH Data Breach Protection and Compliance 2Health News:ID Experts Offers Breach Prevent for Healthcare: A High-Touch, Affordable Solution for HITECH Data Breach Protection and Compliance 3Health News:ID Experts Offers Breach Prevent for Healthcare: A High-Touch, Affordable Solution for HITECH Data Breach Protection and Compliance 4Health News:International Isotopes Inc. Announces Results of the Annual Meeting and Provides an Update on its Depleted Uranium Processing and Fluorine Extraction Process Plant 2Health News:International Isotopes Inc. Announces Results of the Annual Meeting and Provides an Update on its Depleted Uranium Processing and Fluorine Extraction Process Plant 3Health News:International Isotopes Inc. Announces Results of the Annual Meeting and Provides an Update on its Depleted Uranium Processing and Fluorine Extraction Process Plant 4Health News:Avidas(TM) Pharmaceuticals and LaRon(TM) Pharma Inc. Announce Co-Promotion Agreement 2Health News:Avidas(TM) Pharmaceuticals and LaRon(TM) Pharma Inc. Announce Co-Promotion Agreement 3Health News:Avidas(TM) Pharmaceuticals and LaRon(TM) Pharma Inc. Announce Co-Promotion Agreement 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: